Stockscreener 앱 받기
1.46
3.55%
0.05
시장 영업 전:
1.49
0.03
+2.05%
Coherus Oncology Inc 주식(CHRS)의 최신 뉴스
BlackRock (CHRS holder) discloses 8.93M Coherus Oncology shares under sole control - Stock Titan
CHRS|Coherus BioSciences Inc|Price:1.465|Chg%:+0.055 - TradingKey
Coherus Oncology Market Sentiment - Benzinga España
CHRS|Coherus BioSciences Inc|Price:1.410|Chg%:-0.020 - TradingKey
Coherus BioSciences stock trades lower as revenue pressure and patent loss reshape outlook - Ad-hoc-news.de
Coherus Oncology to report Q2 2026 financial results on August 5 - scanx.trade
Coherus BioSciences stock trades around recent lows as revenue declines and oncology pivot continues - Ad-hoc-news.de
Coherus Oncology Announces Date for Second Quarter 2026 Financial Results Conference Call and Webcast - Quiver Quantitative
Coherus Oncology to Report Second Quarter 2026 Financial Results on August 5, 2026 - The Manila Times
Coherus to webcast second-quarter results Aug. 5 at 5 p.m. - Stock Titan
Q3 2025 Coherus Oncology Inc Earnings Call Transcript - GuruFocus
Coherus Oncology | 4: Statement of changes in beneficial ownership of securities-Officer Lanfear Dennis M - Moomoo
Coherus BioSciences stock stays supported by oncology focus - AD HOC NEWS
Coherus Oncology (CHRS) The Citizens JMP Life Sciences Conference 2025 Summary - Quartr
Coherus BioSciences focuses on biosimilars as investors watch Nasdaq listing - Ad-hoc-news.de
Coherus Oncology (CHRS) Hovers Near Support Levels After Slight DeclineFactor Crowding - dars.gov.et
CHRSCoherus Oncology Inc Options - Finviz
Coherus Oncology, Inc. Financial Disclosures & Filings - TradingView
Free cash flow per share of Coherus Oncology, Inc. – SWB:8C5 - TradingView
CHRS Q1 2026 Earnings: Strong EPS Beat Highlights Operational ProgressEarnings Quality Analysis - dars.gov.et
CHRS Q1 2026 Earnings: Narrower-than-Expected Loss Drives Stock GainOperating Income Trends - dars.gov.et
Enterprise value to EBITDA forward of Coherus Oncology, Inc. – NASDAQ:CHRS - TradingView
CHRS Forecast — Price Target — Prediction for 2027 - TradingView
Enterprise value to EBITDA forward of Coherus Oncology, Inc. – LS:A12ETZ - TradingView
CHRS Should I Buy - Intellectia AI
Coherus Oncology, Inc. Actuals & Estimates (NASDAQ:CHRS) - TradingView
8C5 Forecast — Price Target — Prediction for 2027 - TradingView
Price to book forward of Coherus Oncology, Inc. – NASDAQ:CHRS - TradingView
Price to sales forward of Coherus Oncology, Inc. – NASDAQ:CHRS - TradingView
Coherus Oncology (CHRS) Jefferies Global Healthcare Conference 2026 Summary - Quartr
Coherus Oncology (CHRS) Proxy filing Summary - Quartr
Coherus Oncology (CHRS) Enters Clinical Collaboration for Phase 1 Trial - GuruFocus
Coherus Enters Trial Collaboration, Supply Agreement With Zumutor Biologics - marketscreener.com
Coherus and Zumutor announce phase 1 cancer trial collaboration - Investing.com
Coherus and Zumutor announce phase 1 cancer trial collaboration By Investing.com - Investing.com India
Coherus and Zumutor Biologics Announce Clinical Collaboration to Evaluate ZM008 in Combination with LOQTORZI® (toripalimab-tpzi) - The Manila Times
Coherus Oncology and Zumutor Biologics Announce Phase 1 Clinical Collaboration to Evaluate ZM008 in Combination with LOQTORZI - Quiver Quantitative
Coherus and Zumutor Biologics Announce Clinical - GlobeNewswire
Coherus doses first patient in cancer combo trial with Zumutor - Stock Titan
CHRS Q1 2026 Earnings: Narrower Loss Surprises as Coherus Advances PipelineRevenue Inflection Point - dars.gov.et
COHERUS ONCOLOGY INC (CHRS) Stock Chart - ChartMill
Coherus Oncology, Inc. 8-K SEC Filing June 12, 2026 – Entity Information, Common Stock, NASDAQ, and Exhibit Letter from Ernst & Young LLP 18205556 – Minichart - Minichart
Coherus Oncology appoints PwC as new auditor, replaces Ernst & Young - Investing.com Australia
[8-K] Coherus Oncology, Inc. Reports Material Event - Stock Titan
Coherus Oncology (CHRS) Slides 1.41% as Stock Tests Key Support at $1.33Momentum Stock Picks - dars.gov.et
Coherus Oncology (CHRS) director receives 30K RSUs and 60K stock option grant - Stock Titan
[Form 4] Coherus Oncology, Inc. Insider Trading Activity - Stock Titan
Coherus Oncology | 4: Statement of changes in beneficial ownership of securities-Director Wahlstrom Mats - Moomoo
CHRS: Immuno-oncology pipeline advances with key data and global deals expected in 6–18 months - TradingView
CHRS News | COHERUS ONCOLOGY INC (NASDAQ:CHRS) - ChartMill
CHRS Q1 2026 Earnings: Narrower-Than-Expected Loss Despite Negative Stock ReactionEarnings Surprise Report - newsline.com
Coherus Oncology (CHRS) CFO receives repriced $1.59 stock options, cancels higher-strike grants - Stock Titan
Coherus (NASDAQ: CHRS) reprices 3.2M CEO stock options to $1.59 - Stock Titan
Coherus Biosciences Announces 2026 Stockholder Meeting Results - The Globe and Mail
Coherus Oncology | 4: Statement of changes in beneficial ownership of securities-Officer McMichael Bryan J - Moomoo
Coherus Oncology, Inc. 8-K SEC Filing: Company Details, Stock Information, and Compliance Disclosures (May 27, 2026) - Minichart
Coherus Oncology shareholders approve director elections and equity plan changes - Investing.com Canada
Coherus Oncology shareholders approve director elections and equity plan changes By Investing.com - Investing.com South Africa
1.97%
0.83%
자본화:
|
볼륨(24시간):